Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 9/20 | 0.45 |
| ▸ | ACACB | O00763 | 1/20 | 0.43 |
| ▸ | LIPE | Q05469 | 1/20 | 0.43 |
| ▸ | PDE2A | O00408 | 3/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | TEAD1 | P28347 | 2/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3318604 | 0.84 | KDM1A (0.49) | ACACBACHE | |
| SCHEMBL3315251 | 0.82 | ACACB (0.52) | ACACBHRH3 | |
| SCHEMBL3315968 | 0.81 | ADRB2 (0.48) | TEAD1ALDH1A1 | |
| SCHEMBL31613922 | 0.81 | GAA (0.47) | EPHX2PDE2ATEAD1EPHX1ALDH1A1 | |
| SCHEMBL3317146 | 0.79 | L3MBTL1 (0.42) | TEAD1 | |
| SCHEMBL3320631 | 0.79 | CCR5 (0.43) | EPHX2LIPEACHEALDH1A1HRH3 | |
| SCHEMBL3316708 | 0.77 | PDE2A (0.42) | EPHX2PDE2AEPHX1ALDH1A1 | |
| SCHEMBL3310959 | 0.75 | PANK3 (0.42) | EPHX2TEAD1ALDH1A1 | |
| SCHEMBL3320853 | 0.73 | DPP4 (0.45) | ACACBALDH1A1 | |
| SCHEMBL25837687 | 0.72 | PDE2A (0.52) | ACACBPDE2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105651-A1 | ANTAGONISTS OF SNS SODIUM CHANNELS | VERNALIS (R&D) LIMITED (GB) | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105651-A1 | ANTAGONISTS OF SNS SODIUM CHANNELS | CNR1, OPRL1, CHRNA10 | EPHX2 1305/4885ACACB 2762/4885LIPE 1718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.